Study Evaluating The Safety And Tolerability Of ILV-094 In Subjects With Psoriasis
Public ClinicalTrials.gov record NCT00563524. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
AN ASCENDING MULTIPLE DOSE STUDY OF THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND CLINICAL EFFICACY OF ILV-094 ADMINISTERED SUBCUTANEOUSLY OR INTRAVENOUSLY TO SUBJECTS WITH PSORIASIS
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to assess safety, and tolerability of multiple doses of ILV-094 administered to subjects with psoriasis
Study identification
- NCT ID
- NCT00563524
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 76 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 19, 2007
- Primary completion
- Jun 13, 2010
- Completion
- Jun 13, 2010
- Last update posted
- Aug 22, 2024
2007 – 2010
United States locations
- U.S. sites
- 15
- U.S. states
- 10
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| David Stoll, MD | Beverly Hills | California | 90212 | — |
| Dermatology Research | Santa Monica | California | 90404 | — |
| Miami Research Associates | South Miami | Florida | 33143 | — |
| MRA Clinical Research | South Miami | Florida | 33143 | — |
| Hudson Dermatology | Evansville | Indiana | 47714 | — |
| Dawes Fretzin Clinical Research Group | Indianapolis | Indiana | 46256 | — |
| Dawes Fretzin Dermatology Group | Indianapolis | Indiana | 46256 | — |
| Hamzavi Dermatology | Fort Gratiot | Michigan | 48059 | — |
| Central Dermatology | St Louis | Missouri | 63117 | — |
| New York University Medical Center | New York | New York | 10016 | — |
| Mount Sinai School of Medicine | New York | New York | 10029 | — |
| Duke Clinical Reseach Unit | Durham | North Carolina | 27710 | — |
| The Cleveland Clinic Foundation | Cleveland | Ohio | 44195 | — |
| Altoona Center for Clinical Research | Duncansville | Pennsylvania | 16635-0909 | — |
| Baylor Research Institute | Dallas | Texas | 75246-1613 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 9 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00563524, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 22, 2024 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00563524 live on ClinicalTrials.gov.